Gross sales of medical cannabis coated by insurance coverage proceed to extend in Germany, reaching new highs within the second quarter, based on newly launched information.

The regular development in gross sales on this planet’s largest importer of medical marijuana is an effective signal for the worldwide trade, and it comes as a number of nations are gearing as much as begin large-scale MMJ exports.

Medical marijuana reimbursements reached 29.5 million euros ($32.three million) for the April-June interval, up 20% over the earlier quarter, when 24.5 million euros price of medical cannabis was reimbursed by statutory well being insurers.

In contrast with the second quarter of 2018, 74% extra medical cannabis was reimbursed by German insurers year-over-year.

The info, revealed by the German Nationwide Affiliation of Statutory Well being Insurance coverage Funds (GKV-Spitzenverband), consists of all classes of medical cannabis offered by June 2019.

The GKV-Spitzenverband information, although incomplete as a result of it doesn’t embody personal prescription gross sales, presents an excellent estimate of the present dimension of the German market.


Till earlier GKV-Spitzenverband statistical reporting, which corresponds to the primary quarter of 2019, information about Germany’s medical cannabis market had at all times been introduced underneath three broad classes referring to various kinds of merchandise accessible to sufferers:

  • Hashish preparations, together with floor flower prescribed by a health care provider, dronabinol preparations and full-spectrum extracts from Canadian corporations Tilray and Aurora Hashish. No precise numbers for gross sales of every of those three varieties of merchandise throughout the class have been supplied till March 2019.
  • Completed pharmaceutical merchandise, together with Sativex and Canemes, which have advertising authorization in Germany, and different imported completed medicines with out registration equivalent to Marinol. Gross sales of every product on this class have at all times been supplied, with Sativex representing not less than 95% of the class in each current month reported.
  • Unprocessed cannabis flower, with out specifying the producer or the origin.

Till the tip of the second quarter of 2019, all flower was imported from the Netherlands and Canada.

Germany granted its preliminary home cultivation permits in Might, and the primary harvests are anticipated by the tip of 2020.

In current months, the primary shipments of flower from Australia, Colombia, Portugal and Uruguay reached Germany, though product from Latin America was for testing functions solely.

Because the above chart reveals, the brand new GKV-Spitzenverband information, equivalent to the second quarter of 2019, for the primary time removes the cannabis “preparations” class and replaces it with three new classes equivalent to flower utilized in preparations, dronabinol mixtures ready individually and full-spectrum extracts for which the pharmacist solely refills or relabels the product.

This permits for a extra nuanced evaluation of the market as a result of it’s now attainable to know the way a lot flower, full-spectrum extracts and dronabinol mixtures are being reimbursed by insurers.

With this new means of presenting the information, it turns into evident that the sum of “unprocessed flower” and “flower utilized in preparations” represented 55% of the entire reimbursed cannabis merchandise throughout the second quarter of 2019.

As well as, extra flower was offered utilizing personal prescriptions, paid out of pocket by sufferers and never included within the information reported by GKV-Spitzenverband.

What the information says

Might was the highest month for medical protection for cannabis for the reason that present regulatory framework was applied in early 2017.

Throughout that month, statutory well being insurers coated 10.6 million euros of medical cannabis, surpassing the 10 million euro mark for the primary time. The quantity fell to 9.5 million euros in June.

Progress in second-quarter reimbursement is in step with what  Marijuana Enterprise Each day reported in July, indicating that imports surged throughout the interval, based on BfArM.

BfArM’s import information usually particulars solely kilograms of flower. Nevertheless, different merchandise are additionally imported into the German medical cannabis market, however the information shouldn’t be commonly reported by BfArM.

The GKV-Spitzenverband information consists of all classes of cannabis merchandise however reveals solely what statutory well being insurers reimbursed. It doesn’t account for personal prescriptions, which play an essential function within the German market, not less than for flower gross sales.

Reimbursement amongst all classes of merchandise grew, based on the information.

Unprocessed flower and completed pharmaceutical merchandise rose 10% quarter-over-quarter, whereas the “preparations” class grew 38% versus the earlier quarter.

The gross sales information relies on the retail worth at pharmacies, that are the one licensed factors of sale to sufferers in Germany.

For merchandise not included within the “completed pharmaceutical preparations,” pharmacies mark up costs as a lot as 100%.

Alfredo Pascual may be reached at [email protected]